Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC) despite the promise of new targeted and biologic agents. Many studies have shown significant benefit of chemotherapy in the neoadjuvant, adjuvant, and metastatic treatment of TNBC. Neoadjuvant chemotherapy studies have consistently reported higher response rates in TNBC than non-TNBC, and pathologic complete response has been shown to predict improved long-term outcomes for TNBC. Although the specific adjuvant regimens that may be most effective for TNBC are still being determined, third-generation chemotherapy regimens using dose dense or metronomic polychemotherapy are among the most effective tools presently available. The role of specific chemotherapy agents in the treatment of TNBC remains incompletely defined and warrants careful review to ensure that the most effective therapy is delivered while minimizing unnecessary toxicity. Platinum agents have seen renewed interest in TNBC based on a growing body of preclinical and clinical data suggesting encouraging activity. Taxanes and anthracyclines are active in TNBC and remain important agents but have not shown specific benefit over non-TNBC. Capecitabine has limited reported data in TNBC, but some reports suggest differential activity in TNBC compared with hormone receptorpositive breast cancer. TNBC is itself a heterogeneous group in which subgroups such as BRCA1 mutation carriers may have particular sensitivity to platinum agents and relatively less sensitivity to taxanes. Therefore, the identification of additional molecular biomarkers to predict response to specific chemotherapy is required to further improve treatment strategies with the current menu of chemotherapy options and future combinations with targeted therapies.
T he defining characteristic of triple-negative breast cancer (TNBC) is the absence of staining for the estrogen receptor (ER), progesterone receptor (PR), and HER2. 1 This renders TNBC insensitive to some of the most effective therapies available for breast cancer treatment including HER2-directed therapy and endocrine therapy. The lack of known specific therapeutic targets results in a limited arsenal to attack TNBC, primarily consisting of standard cytotoxic chemotherapy. In the metastatic setting, TNBC presents with higher rates of visceral metastases, has a relatively shorter median survival of 7 to 13 months, and has limited duration of response to successive lines of chemotherapy (median response duration of 12 weeks to first line, 9 weeks to second line, and 4 weeks to third line). [2] [3] [4] Therefore, it is important to select the agents most likely to result in a meaningful benefit.
Despite the promise of new targets and new agents such as poly(ADP-ribose) polymerase inhibitors, the treatment of TNBC today demands a critical review of whether TNBC is particularly sensitive to specific types of chemotherapy. This review will focus on the role of standard cytotoxic chemotherapy agents to treat TNBC both for early stage and advanced disease. Herein, the term TNBC is used, with the recognition that TNBC is a histologic characterization that is concordant but not completely synonymous with the molecularly defined basal-like breast cancer subgroup. 1, 5 Because the recognition of TNBC as a potentially distinct subtype of breast cancer is relatively recent, much of the data supporting the use of chemotherapy must be inferred from retrospective analyses that sometimes include only hormone receptor status but not HER2. The emerging novel targeted and biologic therapies for TNBC and their combination with chemotherapy will be described elsewhere in this issue.
THE CASE FOR CHEMOTHERAPY FOR TNBC
The benefits of cytotoxic chemotherapy for the treatment of TNBC are now well established with numerous studies demonstrating the effectiveness of chemotherapy in the neoadjuvant, adjuvant, and metastatic settings. Many of the earlier studies were conducted before the discovery of HER2 and are therefore limited in their direct relevance to TNBC. Nevertheless, in retrospect, the initial observations suggesting that ER levels influence chemotherapy response provided an important foundation for modern trials to build upon. One of the earliest studies to suggest a differential benefit of chemotherapy based on ER status was a retrospective study of 70 patients with metastatic breast cancer. 6 Expression of ER in 25 patients correlated with a response rate of only 12% compared with a response rate of 75% among 45 patients without ER expression. However, a conflicting report published the same year suggested that the response rate to chemotherapy in the metastatic setting was higher in the ER-rich subset compared with the ER-poor subset. 7 The benefit of polychemotherapy in ER-poor breast cancer was evident in the 2005 overview meta-analysis by the Early Breast Cancer Trialists' Collaborative Group. 8 In more than 6000 women with ER-poor disease enrolled in 46 polychemotherapy trials that began before 2000 (but did not include taxanes), a substantial reduction in risk of recurrence and death from breast cancer was seen in younger (10-year hazard ratio [HR] 0.73 and 0.73, respectively) and older patients (10- year HR 0.82 and 0.86, respectively). This analysis is similarly limited by the lack of data on HER2 status in these older trials but is consistent with the notion that TNBC derives substantial benefit from chemotherapy. A retrospective analysis of 3 large Cancer and Leukemia Group B (CALGB) trials including 6444 patients concluded that ER-negative tumors derive substantially greater improvements in outcome from modern intensive and extensive chemotherapy regimens. 9 In comparing the low-dose cyclophosphamide, doxorubicin, fluorouracil (CAF) regimen from CALGB8541 with the dose-dense regimen of doxorubicin, cyclophosphamide followed by paclitaxel (AC-T) in CALGB9741, 10 the relative reduction in risk of recurrence was 55% for ER-negative tumors and 26% in ER-positive tumors. The absolute improvement in risk of recurrence at 5 years was 22.8% for ER-negative tumors and only 7% for ER-positive patients treated with tamoxifen. The concept of dose-intensive regimens demonstrating the greatest improvement in outcome in TNBC is supported by a retrospective study evaluating 236 high-risk patients in the West German Study Group AM-01 study who received a dose-dense regimen of 4 cycles of epirubicin and cyclophosphamide followed by 3 cycles of cyclophosphamide, methotrexate, fluorouracil (CMF) compared with high-dose chemotherapy with peripheral stem cell support. 11 Although high-dose chemotherapy has generally shown no improvement in overall survival (OS), at median follow-up of 62 months, TNBC patients who received high-dose chemotherapy had an improved OS of 76% compared with 61% in the dose-dense arm. Together, these studies support the benefit of chemotherapy, and particularly dose-dense and dose-intensive regimens, for TNBC.
NEOADJUVANT CHEMOTHERAPY FOR TNBC
Several studies have now demonstrated that TNBC has significantly higher pathologic complete response (pCR) rates compared with hormone receptor-positive breast cancer when treated with neoadjuvant chemotherapy (Table 1) , and pCR correlates well with improved outcomes. One of the largest studies to evaluate the response to neoadjuvant therapy in TNBC compared with non-TNBC included 1118 patients treated between 1985 and 2004 at the MD Anderson Cancer Center. 12 The pCR rate in the 23% of patients with TNBC was double that of the non-TNBC subset (22% vs. 11%). The overall 3-year freedom from progression was 63% in the TNBC and 76% in the non-TNBC groups, and the 3-year OS between the groups was 74% and 89%, respectively, confirming the relatively poor prognosis in TNBC. However, patients with TNBC who achieved a pCR had similar 3-year OS as the non-TNBC (94% and 98%, P ϭ 0.24), whereas patients with TNBC who had residual disease after neoadjuvant therapy had a significantly worse 3-year OS (68% vs. 88%, P ϭ 0.0001). These results demonstrate that TNBC has a higher pCR rate compared with non-TNBC after neoadjuvant chemotherapy. TNBC patients who achieve a pCR have an excellent long-term outcome, but those who have less than a pCR are at significantly higher risk of recurrence and death than patients with non-TNBC. A similar retrospective study in an overlapping data set of 1731 patients from the same institution who received preoperative chemotherapy between 1988 and 2005 found an overall pCR rate of 13%. 13 The 67% of patients who were hormone receptor positive achieved a pCR rate of 8% compared with 24% for the hormone receptor-negative patients. Further subgroup analysis identified 317 patients with triple-negative tumors who achieved a pCR rate of 22.4%. There were too few triple-negative patients to correlate OS with pCR, but the hormone receptor-negative patients who achieved a pCR had a 10-year OS of 84% compared with only 59% for those without a pCR. Together, these retrospective studies support the conclusion that achieving pCR is a strong predictor of long-term favorable outcome in TNBC.
Additional smaller retrospective studies confirm these findings. In a retrospective study of 151 patients receiving neoadjuvant anthracycline-and taxane-based therapy, those patients with TNBC (14%) had significantly higher pCR rates compared with non-TNBC (38% vs. 12%). 14 Patients who achieved a pCR had a prolonged disease-free survival (DFS), and among patients who did not achieve a pCR, the TNBC subgroup had a significantly worse prognosis. A retrospective study of 435 patients who received neoadjuvant therapy for breast cancer between 1985 and 2003 found that ERnegative tumors were more likely to achieve a pCR than ER-positive tumors (21.6% vs. 8.1%). 15 Overall survival at 5 years was higher in the ER-negative subgroup who achieved a pCR compared with those who did not (90% vs. 52%) in agreement with other studies. In 399 patients treated preoperatively between 1994 and 2002, overall 15.7% had a pCR. 16 In the 129 hormone receptor-negative patients, the pCR rate was 33.3% compared with 7.6% in the hormone receptor-positive group. In this study, HER2 was evaluated but the combined hormone receptor-negative/HER2-negative subgroup was not independently reported. In contrast to other studies, this study reported that patients who achieved a pCR had a slightly worse prognosis than those who did not achieve pCR. The higher proportion of hormone receptor-negative patients in the pCR group may account for this finding, reflecting the worse overall prognosis of the hormone receptor-negative group. However, in this study, pCR was defined as a complete or near complete response in the breast only, not including the nodes. Therefore, it is likely that the less strict definition of pCR also accounts for this finding.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-27 trial randomized 2411 women to 1 of the 3 arms to evaluate the response to neoadjuvant therapy and long-term outcomes. Patients received either 4 cycles of standard AC every 3 weeks followed by surgery, 4 cycles of AC followed by 4 cycles of docetaxel (D) and then surgery, or 4 cycles of AC followed by surgery and then 4 cycles of adjuvant docetaxel. Determination of hormone receptor status was not required for study entry. The addition of preoperative docetaxel nearly doubled the pCR rate from 12.9% and 14.4% in each of the 2 AC arms to 26.1% in the AC-D arm. 17 Interestingly, subgroup analysis showed that the pCR rate nearly doubled with the addition of docetaxel for both the ERϩ and ERϪ tumors, from 5.7% to 14.1% and 13.6% to 22.8%, respectively. However, the pCR rate of the ERϪ subset itself was nearly double than that of the ERϩ subset in each treatment group (5.7% vs. 13.6% for AC and 14.1% vs. 22.8% for AC-D). Notably, the pCR rate of the ERϪ "unknown" group was 31.6% and 50.8% for the AC and AC-D cohorts, respectively. However, this is an artifact because the technology to assess receptor status in diagnostic core biopsies was not uniformly present during the time of this study and ER status could not be determined in tumors that had a pCR because no tumor tissue was present at surgery. Retrospective analysis of samples from the NSABP B-27 to confirm hormone receptor and HER2 status is ongoing and may yield further insight into the response to preoperative chemotherapy. Of the 2411 patients enrolled, over 300 samples are available for analysis and nearly one-third are hormone receptor negative. Surprisingly, the addition of docetaxel did not result in improved DFS or OS in an updated analysis. 18 However, this trial has several significant limitations affecting its interpretation: pCR was defined as no residual tumor in breast but did not consider the lymph nodes; tamoxifen was started concurrently with chemotherapy in all patients; the majority of patients had unknown hormone receptor status because of technical limitations at the time; and the trial was significantly underpowered to detect the difference in OS that might have been expected.
The GEPARDUO (German Preoperative Adriamycin Docetaxel) trial also evaluated the pCR rate in 913 women randomized to receive preoperative doxorubicin and docetaxel for 4 cycles or doxorubicin and cyclophosphamide for 4 cycles followed by docetaxel for 4 cycles. 19 The overall pCR rate was only 10.6% in all patients combined, with an improvement from 7.0% to 14.3% with the 3-drug regimen. However, the ERϪ subgroup was 3 times more likely to achieve a pCR compared with the ERϩ subgroup (22.8%
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The Cancer Journal • Volume 16, Number 1, January/February 2010 The Cancer Journal • Volume 16, Number 1, January/February 2010 Triple-Negative Breast Cancer vs. 6.2%). Although HER2 status was not reported in the original study, a recent analysis of samples from the GEPARDUO trial confirmed that the triple-negative subgroup had significantly higher pCR than the hormone receptor-positive subgroup. 20 The prospectively designed I-SPY trial of 190 patients who received neoadjuvant anthracycline-and taxane-based therapy included 28% patients with TNBC who had a pCR rate of 33%, compared with hormone receptor-positive, HER2Ϫ patients who had only a 10% pCR rate. 21 A study evaluating preoperative chemotherapy in basal-like breast cancer treated with 12 weeks of weekly paclitaxel followed by 4 cycles of fluorouracil, doxorubicin, cyclophosphamide (FAC) revealed a pCR rate of 45%. 22 Of the 22 basal-like tumors in that study, 21 (95%) were ERϪ and 19 (86%) were HER2Ϫ. The pCR rates of the luminal A/B (n ϭ 30), normal breast-like (n ϭ 10), and HER2ϩ (n ϭ 20) molecular subtypes were 7%, 0%, and 45%, respectively. 22 This supports the conclusion that basal-like breast cancer is more highly sensitive to paclitaxel and doxorubicin chemotherapy and correlates with similar results seen with histologic markers defining TNBC. Carey et al 23 evaluated the response rate to anthracycline-based preoperative therapy in a retrospective study of 107 patients treated between 1998 and 2003. Among the triplenegative tumors that were classified as basal like, the clinical 
The Cancer Journal • Volume 16, Number 1, January/February 2010 response rate was 85% and the pCR rate was 27%. The HER2ϩ subset had similar response rates, but the luminal A and B subsets of the hormone receptor-positive tumors had a pCR rate of 0% and 15%, respectively. There were no recurrences among the basal-like cancers that achieved a pCR, but the distant DFS of all patients with basal-like cancer was only about 60%. A similar result was seen in a study of 145 patients with stage 2 or 3 breast cancer who received preoperative doxorubicin and docetaxel for 3 cycles, followed by surgery and adjuvant chemotherapy with an additional 3 cycles of the same regimen. In this study, tumors with Ͻ10% ER staining were considered negative, which is a higher cut-off than most studies use. The overall pCR rate was 8%, but among the one-third of patients with TNBC, the pCR rate was 17% compared with only 3% for the non-TNBC group. 24 Overall, the above data clearly indicate that TNBC has a higher response to neoadjuvant chemotherapy resulting in significant improvements in pCR compared with hormone receptor-positive tumors. The improvements were seen with a variety of different agents and raise the question of whether specific chemotherapy agents are more active than others.
PLATINUM AGENTS: ARE THEY SPECIFIC TO TNBC?
The use of platinum agents for breast cancer has a long history dating to the early 1970s and includes more than 200 clinical trials in breast cancer patients (unpublished observation). 25 Platinum agents were initially tested in patients with advanced breast cancer, both as a single agent and in combination with other drugs, and were shown to be active when given early in the course of the disease. However, platinum agents were not readily adopted, perhaps because of the superior therapeutic index of other drugs under development at the time, notably the taxanes. Small studies demonstrated objective response rates ranging from 42% to 54% with the use of cisplatin as a single agent, but response rates were lower in women who had received prior chemotherapy for metastatic disease. 26 -28 When cisplatin was given after other chemotherapy, the response rate fell to 0% to 9%. 29 -33 Notably, these studies used cisplatin in patients regardless of ER, PR, and HER2 status. Several combination regimens were also explored, particularly cisplatin combined with taxanes, but there seemed little reason to continue these combinations when the taxanes were found to be highly active and relatively less toxic. 34 Recently, there has been renewed interest in platinum agents for the treatment of TNBC, in part because of improved strategies for managing its side effects, and because of additional preclinical data that suggested they may be particularly active in TNBC and BRCA1-associated breast cancer. Breast tumors arising in BRCA1 mutation carriers share features with the basal-like tumors. 35, 36 However, although nearly all BRCA1 tumors are basal-like, not all basal-like tumors have BRCA1 mutations. Several groups have demonstrated that tumor cell lines (human breast and ovary) deficient in BRCA1 are unusually sensitive to the DNA cross-linking agents, including cisplatin and mitomycin, and that this sensitivity is reversed with either BRCA1 up-regulation or restoration of BRCA1 function. [37] [38] [39] [40] [41] [42] In 1 study, treatment with cisplatin produced a dosedependent reduction in cell growth in breast cell lines after 48 hours of treatment. 41 The BRCA1 defective cell line was 2-to 3-fold more sensitive to cisplatin compared with BRCA1-competent cell lines. This data suggests that cisplatin may be a good agent for BRCA1mutated breast cancer.
The histologic similarities between BRCA1-mutated breast cancer and TNBC raised the possibility that triple-negative tumors may also demonstrate relative sensitivity to cisplatin. Recent clinical and preclinical work from our institution and others has identified that platinum agents, such as cisplatin and carboplatin, may be particularly active in a subset of patients with TNBC. Recently, a molecular pathway by which cisplatin induces cell death selectively in TNBC has been discovered ( Fig. 1 ). 43 Inactivation of this pathway increases the IC 50 of breast cancer cells for cisplatin 10-to 100-fold. These findings have led to the discovery of a biomarker present in 30% to 50% of TNBC that may define which tumors will exhibit clinical sensitivity to cisplatin. However, it remains controversial whether platinum agents are particularly beneficial in TNBC compared with other subtypes. For example, in a retrospective study evaluating 802 patients with metastatic breast cancer, 67 were identified as having measurable disease who also received a platinumand paclitaxel-based regimen in the first or second line. The overall response rate (ORR) among the 67 patients was 38.8%. In the subset with TNBC, the ORR was similar, 37.5%, and there was no difference compared with the hormone receptor-positive subgroup. 44
Preoperative Studies
Preoperative therapy with platinum has yielded promising results (summarized in Table 1 ). Our institution conducted a preoperative phase II study evaluating single agent cisplatin (75 mg/m 2 ) given for 4 cycles to women with stage 2 or 3 TNBC. 45, 46 The pCR rate was 22% (6 of 28) and 36% had a Miller-Payne score of 4 or 5, which includes complete and near-complete responses. Two patients in this study were BRCA1 carriers and both achieved a pCR. A preliminary biomarker assessment of p63/p73 expression in the 22 available samples demonstrated that a pCR was achieved in 3 of 9 biomarker-positive patients (33%) but only 1 of 13 biomarker-negative patients (7%). 46 A follow-up study evaluating preoperative cisplatin plus bevacizumab in 51 patients resulted in a pCR rate of 16%, with 37% achieving a Miller-Payne score of 4 or 5. 47 Together, both studies suggest that single agent cisplatin is active in untreated TNBC.
Platinum agents have also been used in combination with other agents in the neoadjuvant setting. A 2004 phase II study of preoperative paclitaxel and cisplatin demonstrated a 28% complete FIGURE 1. Mechanism of p63/p73 mediated platinum sensitivity in triple-negative breast cancer. Approximately onethird of triple-negative breast cancers express the p53 family members ⌬Np63␣ and TAp73. In proliferating cells, ⌬Np63␣ inhibits apoptosis by forming heterodimers with TAp73 and forming homotetramers that bind to the promoters of TAp73 target genes, thereby preventing transcription of proapoptotic genes. Cisplatin treatment induces DNA damage resulting in activation of the c-ABL tyrosine kinase and phosphorylation of TAp73. TAp73 then forms stable homotetramers that bind to TAp73 target genes such as PUMA and NOXA resulting in apoptosis. Expression of p63/p73 in breast cancer cell lines results in 10-to 100-fold greater sensitivity to platinum chemotherapy.
The Cancer Journal • Volume 16, Number 1, January/February 2010 Triple-Negative Breast Cancer response rate and a 63% partial response rate in patients enrolled without regard to ER, PR, and HER2 status. 48 A study of 88 patients with locally advanced breast cancer who received preoperative cisplatin-containing regimens (doxorubicin and paclitaxel for 4 cycles followed by cisplatin and paclitaxel for 4 cycles in either order) demonstrated a pCR rate of 35% in the ER-negative, HER2negative subset. A remarkably high pCR rate of 65% was seen in 74 patients with TNBC treated with cisplatin 30 mg/m 2 , epirubicin 50 mg/m 2 , and paclitaxel 120 mg/m 2 weekly for 8 weeks with GCSF support on days 3 to 5. 49 Adjuvant therapy with 4 cycles of CMF was administered to all patients, and those with 4 or more positive nodes after preoperative therapy received an additional 4 cycles. Those patients who achieved a pCR had a 3-and 5-year DFS of 97% and 90%, respectively, compared with 3-and 5-year DFS rates of 61% and 56% in those with residual disease after preoperative therapy. Notably, about equal numbers of patients had T2 and T3 tumors, but the pCR rate was significantly higher in the T2 tumors (74% vs. 51%). A similar study of 30 patients treated with preoperative epirubicin, cisplatin, and fluorouracil (ECF) ϫ 4 followed by weekly paclitaxel resulted in a pCR rate of 43%. 50 In a retrospective study of patients who received platinum-containing regimens, significantly higher clinical responses were seen in the neoadjuvant and metastatic setting in the triple-negative subgroup. 51 The role of platinum in early-stage treatment of TNBC will be addressed in 2 randomized phase II studies. The CALGB40603 study is a 2 ϫ 2 factorial design evaluating Ϯcarboplatin and Ϯbevacizumab added to preoperative weekly paclitaxel followed by dose-dense AC in hormone receptor-poor, HER2Ϫ breast cancer. The Spanish Breast Cancer Research Group is evaluating preoperative epirubicin, cyclophosphamide (EC) ϫ 4 followed by docetaxel Ϯ carboplatin in TNBC. These 2 prospective studies will help address the important question of whether addition of platinum agents improves outcomes in TNBC; because pCR correlates with improved long-term outcomes in TNBC, the added benefit of platinum on the pCR rate may predict a benefit on DFS and OS. In addition, these trials will provide a rich opportunity to evaluate predictive biomarkers of platinum sensitivity.
The activity of platinum in the BRCA1 population specifically has recently been demonstrated in several intriguing studies. In a study of 25 BRCA1 patients in Poland in whom 80% were triple-negative (and 3 had incomplete data), a pCR rate of 72% was achieved with preoperative single agent cisplatin (75 mg/m 2 ) administered every 3 weeks for 4 cycles. 52 In a related retrospective study among 102 consecutive BRCA1 carrier patients treated with a variety of preoperative regimens, cisplatin alone achieved a pCR rate of 83% compared with significantly lower rates with CMF, AC, CAF, or doxorubicin, paclitaxel (AT) (7%, 22%, 21%, 8%, respectively). 53
Metastatic Studies
In addition to the evaluation of platinum in the preoperative setting, studies in the metastatic setting further support that platinum may be active in advanced TNBC. The Translational Breast Cancer Research Consortium 001 study evaluated 100 patients with metastatic TNBC randomized to cetuximab with or without carboplatin (area under the curve ϭ 2) given weekly for 3 weeks every 28 days in up to the third-line setting. 54 Patients crossed over to the combination arm upon progression after single agent cetuximab. A response rate of 18% was observed in the combination arm. The identification of the potential biomarker p63/p73 to predict response to platinum has led to the Translational Breast Cancer Research Consortium 009 trial in 82 patients with TNBC that will address 2 important questions. 55 First, it will define the single agent response rate to cisplatin (75 mg/m 2 ) or carboplatin (area under the curve ϭ 6) given every 3 weeks in the first or second line. Second, it will determine prospectively whether p63/p73 expression predicts response to platinum. In a small trial of 15 patients with BRCA1 mutations with metastatic breast cancer treated with single agent cisplatin every 3 weeks, of whom 10 had TNBC, the ORR was 72% with 7 patients reported to have clinical complete responses. 56 The large randomized phase III Triple-Negative Breast Cancer Trial (TNT) with approximately 400 patients in the UK is underway comparing carboplatin with docetaxel for metastatic TNBC. 57 The primary end point of the trial is response rate, and a series of secondary end points and exploratory studies will be undertaken to evaluate OS and identify predictors of response to better define the platinum responsive subgroup of tumors. Patients may receive up to 6 cycles of treatment and will crossover to the other arm at progression. The TNT study is designed to detect a 15% improvement in response to carboplatin compared with docetaxel.
This trial will answer a critical question in the management of TNBC to help define how platinum should be used in metastatic disease.
Despite the intriguing data suggesting that platinum may be active in TNBC, there is presently no established role for adding platinum to early-stage regimens outside of a clinical trial. In the metastatic setting, it is reasonable to consider platinum in the armamentarium of available agents, but there is still insufficient data to recommend its use over standard chemotherapy in early lines. This may change as a result of ongoing studies discussed above. Data in BRCA carriers are particularly exciting, and the results of prospective studies are eagerly awaited.
TAXANES
The benefit of taxanes in adjuvant therapy for TNBC has been realized over the past few years. The first trial that established the benefit of paclitaxel added to AC was CALGB9344/INT1048. This trial randomized 3121 patients with node-positive operable breast cancer in a 3 ϫ 2 schema to receive 3 different doxorubicin doses followed by further therapy with or without 4 cycles of paclitaxel every 3 weeks. The addition of paclitaxel resulted in a 17% reduction in the risk of recurrence and 18% reduction in the risk of death, with an improvement in 5-year DFS and OS from 65% to 70% and 77% to 80%, respectively. 58 The initial study did not evaluate HER2 status, but an unplanned subset analysis of hormone receptor status suggested that the hormone receptor-negative subgroup had an improved HR for recurrence of 0.72 (95% CI 0.59 -0.86) compared with a HR of 0.91 (95% CI 0.78 -1.07) for the receptor-positive subset. However, this was not considered statistically significant when corrected for multiple comparisons. In an important subsequent analysis of this trial, a subset of 1322 patients was evaluated for the impact of HER2 status on outcomes. 59 Paclitaxel was associated with improvements in DFS in the HER2-positive patients regardless of hormone receptor status, whereas in HER2-negative patients, benefit was only seen in the hormone receptor-negative group. Although PR was not formally reported in this study, this exploratory analysis suggests that the triple-negative subset of breast cancer derives substantial benefit from the addition of paclitaxel in the adjuvant setting, supporting the conclusion that taxanes are important in TNBC.
A large trial of 4950 patients randomized to receive adjuvant doxorubicin and cyclophosphamide followed by docetaxel or paclitaxel given weekly or once every 3 weeks demonstrated an overall improvement in 5-year DFS and OS of 27% and 32%, respectively, 60 in favor of weekly paclitaxel over paclitaxel every 3 weeks. In the triple-negative subgroup, the benefit of weekly paclitaxel was 37% over the 3-week regimen. Thus, not only is paclitaxel effective in this setting but also the weekly regimen is more active than the less frequent 3-week regimen. Further support
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The Cancer Journal • Volume 16, Number 1, January/February 2010 for the benefit of taxanes for ER-negative tumors comes from a retrospective analysis of 1079 patients who received preoperative chemotherapy in clinical trials with or without taxanes. 61 In the ER negative subgroup, pCR was achieved in 15% without taxanes and 29% with taxanes. A preoperative study of paclitaxel followed by FAC resulted in a 45% pCR rate among the basal subgroup of patients, 22 further supporting the benefit of taxanes in this subgroup. However, conflicting data have been reported on the specific benefit of taxanes for adjuvant therapy in TNBC. A subset analysis of the BCIRG001 trial evaluated the benefit of docetaxel versus fluorouracil when added to doxorubicin and cyclophosphamide (TAC vs. FAC) in molecular subgroups. 62, 63 The benefits of docetaxel were independent of hormone receptor status. In addition, the NSABP B28 trial compared doxorubicin and cyclophosphamide with or without 4 cycles of paclitaxel in 3060 patients and found no statistically significant difference in the relative risk of recurrence and OS based on hormone receptor status. 64 Similar to the BCIRG001 trial and the initial analysis of CALGB9344, the HER2 status of tumors in NSABP B28 was not known. However, the majority of the hormone receptor-negative subgroup is likely comprised of TNBC.
As with platinum agents, the BRCA1 population may demonstrate distinct patterns of response to taxanes compared with sporadic TNBC. Two retrospective studies from Poland evaluated the response to neoadjuvant therapy with docetaxel regimens. Among 44 BRCA1 carriers identified in a registry of 3479 patients, only 6 of 15 who received docetaxel and doxorubicin had a complete or partial response, compared with 29 of 29 who received nontaxane, DNA damaging regimens. 65 A second retrospective study from Poland of 175 patients with metastatic breast cancer treated with docetaxel-based regimens identified 19 with primary resistance to docetaxel. 66 Mutations in BRCA1 were found in 5 of the 19 (26%), and all 5 were in the TNBC subgroup, suggesting that BRCA1 mutation might confer decreased response to docetaxel. This question will be answered in the UK-based BRCA trial, which is similar in design to the TNT trial, comparing carboplatin and docetaxel for first-line treatment of metastatic breast cancer only in BRCA carriers.
In the metastatic setting, several trials suggest a lack of specific benefit for taxanes for TNBC over other subtypes and generally support the conclusion that taxanes are effective in all subtypes of breast cancer. In the CALGB9342 trial, which evaluated 3 different doses of paclitaxel for metastatic breast cancer, there was no statistically significant difference in response rate or time to treatment failure between TNBC and hormone receptor-positive tumors. However, the OS was significantly worse for the TNBC compared with hormone receptor positive. 67 The Eastern Cooperative Oncology Group 2100 study randomized 722 patients to initial chemotherapy with paclitaxel with or without bevacizumab. 68 More than 90% of the patients were HER2 negative and more than a third were ER and PR negative, suggesting that a majority of the hormone receptor-negative patients were likely triple-negative. All subgroups showed a similar benefit with the addition of bevacizumab. Interestingly, however, the progression-free survival was only 4.6 months for the hormone receptor-negative subset in the paclitaxelalone arm, compared with 8.0 months in the hormone receptorpositive group. As with the CALGB9342, this likely reflects the poor prognosis of hormone receptor-negative disease.
Although there does not seem to be a specific benefit of taxanes for TNBC in the metastatic setting, as mentioned above, BRCA function may play a role in taxane sensitivity. Preclinical data demonstrate that intact BRCA1 function contributes to antimicrotubule agent sensitivity. 40 Therefore, if sporadic TNBC also has a functional deficiency of BRCA1, then it follows that TNBC may be more resistant to taxanes. This question will be addressed in the phase III TNT study discussed above, comparing carboplatin and docetaxel. The search for additional biomarkers to predict platinum sensitivity in TNBC may yield additional insights. For example, TNBC was shown to have more frequent expression of caveolin-1. 69 Interestingly, 1 mechanism of cellular uptake of nanoparticle-albumin bound paclitaxel (nab-paclitaxel) is via caveolin-1-dependent receptormediated transcytosis. Therefore, the use of nab-paclitaxel may warrant further testing for TNBC with high caveolin-1 expression. 70 
ANTHRACYCLINES
The benefit of anthracycline-based therapy is supported by several studies described in the section on preoperative therapy above. However, TNBC may be heterogeneous and it remains unclear with regard to anthracycline sensitivity whether BRCA1 associated TNBC is functionally similar to sporadic TNBC. A provocative study suggests that BRCA1-associated TNBC may be less sensitive to anthracycline-based therapy. 71 Among 55 triplenegative patients who received 6 cycles of FEC100 (fluorouracil/ epirubicin 100 mg/m 2 /cyclophosphamide), 12 BRCA1 carriers were identified. The pCR rate for the 12 triple-negative BRCA1 carriers was 17% compared with 42% in the 55 sporadic triple-negative noncarriers. However, other studies come to different conclusions and suggest that BRCA1/2 mutation carriers do indeed have high pCR rates to anthracyclines. 72 Although most studies support a benefit for anthracycline-based regimens, a recent analysis from the MA5 study comparing adjuvant cyclcophosphamide, epirubicin, fluoruracil (CEF) to CMF showed an improvement in 5-year OS in the CMF arm for TNBC (71% vs. 51%), whereas the CEF arm was superior in all other subgroups. 73 
CAPECITABINE
The efficacy of capecitabine has not been prospectively studied in TNBC and there remains relatively scant data on its activity in this group. However, several observations can be made from retrospective subgroup analyses and several trials are underway to evaluate capecitabine in TNBC. In CALGB49907, standard adjuvant chemotherapy (either CMF or AC) was compared with capecitabine in women older than 65 years to determine noninferiority. 74 After 600 patients were enrolled, the trial found capecitabine was inferior to standard chemotherapy with a HR of 2.09. Importantly, a planned subgroup analysis revealed that the benefit of standard chemotherapy was most pronounced in hormone receptor-negative patients compared with hormone receptor-positive patients (HR 3.04 for relapse-free survival, 2.62 for OS). The analysis of the TNBC subgroup is ongoing, but because of the small numbers of HER2 positive tumors in this trial, the results are likely to be similar.
In the metastatic setting, 2 randomized phase III trials compared capecitabine plus ixabepilone with capecitabine monotherapy in 1712 patients treated with prior anthracycline and taxane therapy. 75 In a combined subgroup analysis, 857 total patients received capecitabine alone, of which 208 patients had TNBC. The ORR and PFS in the capecitabine monotherapy arm was 25% and 4.2 months in the overall population, but only 15% and 1.7 months in the TNBC subgroup. A single-arm phase II study of capecitabine with bevacizumab found nearly double the response rate in ERϩ patients compared with triple-negative patients (47% vs. 27%) with a similar difference in time to progression (8.9 vs. 4.0 months) and OS (Ͼ16.6 vs. 7.5 months). 4 Results from such studies have caused some to conclude that capecitabine may be less effective in TNBC. However, additional data are needed before concluding that capecitabine has limited activity in TNBC.
The Cancer Journal • Volume 16, Number 1, January/February 2010 Triple-Negative Breast Cancer SUMMARY Cytotoxic chemotherapy remains the backbone of current treatment strategies for TNBC because of a lack of known specific therapeutic targets. The benefits of chemotherapy for TNBC have now been clearly demonstrated in multiple studies in the early and advanced stages. Although the specific adjuvant regimens that may be most effective for TNBC are still being determined, there is general consensus that third-generation chemotherapy regimens utilizing polychemotherapy administered in a dose dense or metronomic manner are, at the moment, the most effective tools available 76 and may preferentially provide greater benefit for TNBC over other subtypes of breast cancer. Neoadjuvant chemotherapy has consistently demonstrated higher response rates for TNBC than non-TNBC, and pCR predicts improved long-term outcomes for TNBC. However, the potential selective benefit of specific chemotherapy agents over others warrants careful evaluation to select the therapy most likely to provide benefit to an individual patient while minimizing unnecessary toxicity. Platinum agents have seen renewed interest in TNBC based on a growing body of preclinical and clinical data suggesting encouraging activity. Two of the most important ongoing randomized trials are CALGB40603, evaluating the benefit of carboplatin added to paclitaxel and AC, and the Triple-Negative Trial, evaluating carboplatin against docetaxel. Each of these trials will help define the role of platinum agents for early and advanced TNBC, and importantly will provide rich resources to identify potential tissue biomarkers to help define subgroups of patients with TNBC most likely to benefit from platinum agents. At the moment, however, there is no established role for adding platinum agents to early-stage regimens outside of a trial, and their role in the metastatic setting remains poorly defined but reasonable to consider. Taxanes and anthracyclines are active in TNBC and remain important agents, but have not shown specific benefit over other subgroups. Capecitabine has limited reported data as monotherapy in TNBC, but some reports raise concerns that it may be less active in TNBC compared with hormone receptorpositive breast cancer. Although recent efforts have tried to categorize response to specific chemotherapy based on histologic subsets of breast cancers, it is also becoming clear that the TNBC itself is a heterogeneous group. For example, limited data suggests BRCA1 mutation-associated TNBC may have particular sensitivity to platinum agents and relatively less sensitivity to taxanes. Therefore, identification of additional molecular biomarkers to predict response to specific treatments is required to further improve our treatment strategies with current chemotherapy options and future combinations with targeted therapies.
